SINTX Technologies (SINT) Q2 2026 earnings summary

Executive summary

• Transitioned from a development company to a commercially focused biomaterials and medical technology platform, with commercial activity now visible in financial results.

• Advanced ceramics company focused on silicon nitride-based biomedical and industrial applications, with recent FDA clearance for a new orthopedic device and initial commercial sales in 2026.

• Strategic shift toward healthcare sector, leveraging proprietary materials for growth, while maintaining industrial product lines as a revenue foundation.

• Broadened application of proprietary silicon nitride technology across healthcare and industrial markets.

• Investments in advanced manufacturing and cost management initiatives to support growth.

Financial highlights

• Q2 2026 revenue rose 199% year-over-year to $452,000; product revenue up 347% to $447,000.

• Gross profit increased 388% to $278,000; gross margin improved to 61.5% from 37.7% a year ago.

• Net loss was $2.7 million, compared to $2.3 million in Q2 2025; six-month net loss was $5.5 million, up from $4.6 million year-over-year.

• Cash and cash equivalents were $3.6 million at June 30, 2026; stockholders' equity was $4.8 million.

• Inventory increased to $2.3 million, reflecting preparation for anticipated demand.

Outlook and guidance

• Q3 2026 revenue expected to be $900,000–$1.1 million; Q4 2026 revenue expected at $1 million–$1.3 million.

• Guidance subject to significant uncertainty due to production timing, customer scheduling, and revenue recognition.

• Management expects continued operating losses and negative cash flow, with ongoing efforts to raise additional capital and focus on high-growth healthcare applications.

• Animal studies for antipathogenic suture and wound care technologies to begin in Q3 2026, with preliminary data expected by year-end.

• Management believes multiple commercial and development programs will drive future growth across medical and industrial markets.